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Burkitt's lymphoma
BimELV) generally latently infects its target cells with expression of genes conferring
resistance to apoptosis. However, the modulation of apoptotic signals during lytic cycle remains poorly
understood. We show here that resulting from viral reactivation in the EBV-positive Mutu-I and Akata
Burkitt's lymphoma cell lines, a two steps proteasome-dependent downregulation of expression of the
proapoptotic protein BimEL occurs. The ﬁrst drop might be EBV-independent, is ERK 1/2 dependent, and
BimEL is phosphorylated on Ser69. A second dramatic drop of the BimEL level observed during the lytic cycle
is dependent of EBV-late-gene expression, ERK 1/2 independent, and no further phosphorylation of BimEL
on Ser69 occurred. These results demonstrate for the ﬁrst time, that the lytic cycle contributes to
downregulation of BimEL and then could add to protection against apoptosis.
© 2009 Elsevier Inc. All rights reserved.IntroductionEpstein–Barr virus (EBV) is a persistent and widespread human
gamma herpesvirus, infecting more than 90% of the adult human
population. The virus is associated with the development of
lymphomas (Kieff and Rickinson, 2007). EBV infects latently its target
cells and expresses a limited subset of viral genes. EBV infection leads
to the immortalization of B-lymphocytes, which is associated with an
increase in the resistance of transformed cells to various apoptotic
stimuli. Latent infection leads to downregulation of the proapoptotic
BH3-only Bcl-2 interacting mediator of cell death, Bim protein
(Clybouw et al., 2005, 2008) which is particularly important in the
regulation of apoptosis during B-cell development. Three Bim
proteins, BimEL (extra large), BimL (large) and BimS (small) are
synthesized from the same transcript.
In vitro, different agents induce the EBV lytic cycle, including
phorbol 12-myristate 13-acetate (PMA) (Zur Hausen et al., 1978),
cross-linking of surface immunoglobulin (Takada, 1984) and trans-
forming growth factor beta 1 (TGF-β1) (Fahmi et al., 2000). The
switch from latent to lytic cycle is regulated by two immediate-earlyll rights reserved.proteins ZEBRA (Zta, EB1) and Rta, which are encoded respectively by
the EBV BZLF1 and BRLF1 genes (Feederle et al., 2000) leading to
expression of early (mainly linked to DNA replication) and late genes
that encode principally virion proteins such as Viral Capsid Antigens
(VCA). The expression of late genes is abolished by the viral DNA
synthesis inhibitor phosphonoacetic acid (PAA). The lytic cycle
ultimately leads to the production of the progeny virions (Pattle and
Farrell, 2006). Lytic EBV gene expression might also modify apoptotic
process since EBV encodes two lytic anti-apoptotic proteins BHRF1
(Howell et al., 2005) and BALF1 (Altmann and Hammerschmidt,
2005). It has been noticed that Akata cells very late in EBV replication
remained viable by dye exclusion and highly functional (Yuan et al.,
2006). Moreover, Inman et al. (2001) showed that late EBV gene
products are required for effective protection of infected B cells from
apoptotic death. This led us to investigate the modulation of pro- or
anti-apoptotic signalling pathways during EBV lytic cycle.
This work was focused on the regulation of the level of Bim protein
during lytic cycle, in cell lines derived from in vivo EBV-infected BL.
We report here that during EBV reactivation, a two steps down-
regulation of expression of the proapoptotic protein BimEL occur. The
ﬁrst drop is ERK 1/2 dependent and might be EBV-independent and a
second dramatic drop of the BimEL level is dependent of EBV-late-
gene expression.
Fig. 2. EBV-late-gene expression contributes to BimEL degradation during virus
reactivation. (A) Mutu-I cells were pretreated or not for 1 h with PAA and then
stimulated with TGF-β1 for 4, 8, 16, or 48 h. At the indicated time, cells were harvested,
washed, lysed; extracts were analyzed by western blotting against BimEL, phospho-ERK
1/2, ERK 1/2, ZEBRA, VCA and tubulin (loading control). Antibody binding was detected
by enhanced-chemiluminescence (West-pico or femto; Pierce Biotechnology). Images
were captured using a DDC camera (LAS-1000; Fuji system). (B) The signal was
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Expression of Bcl-2 family of proteins in EBV-reactivated BL cell lines,
Mutu-I and Akata
To investigate whether EBV reactivation might directly modulate
apoptosis in a B lymphoma cell context, we used two EBV-positive
BL-derived cell lines Mutu-I, and Akata as previously described
(Touitou et al., 2003). EBV lytic cycle was achieved by treatment of
Mutu-I, and Akata cells respectively with 2 ng/ml of TGF-β1 or
7.5 μg/ml of anti-Ig in a reduced fetal calf serum medium
concentration (0.5%). Seventeen hours later, cells were lysed, probed
by western blot for ZEBRA and for apoptosis regulating proteins
including Bcl-2, Bcl-xL, Bid, Puma, Bax and Bim. As shown in Fig. 1,
TGF-β1, and anti-Ig treatment efﬁciently induces EBV reactivation in
BL cell lines as judged by the induction of ZEBRA protein.
Immunoblot analysis performed on the same cell extracts showed
that while the protein levels of Bcl-2, Bcl-xL, Bid, Puma, Bax or the
BimL and BimS isoforms varied between cell lines (Mutu-I and
Akata), a non consistent difference was observed with the induction
of EBV lytic cycle. In contrast, the level of BimEL was reduced
dramatically during virus reactivation. Similar results were observed
48 h post induction with TGF-β1, and anti-Ig in Mutu-I, and Akata
cells respectively (not shown).
Effect of EBV-late-gene expression on the disappearance of BimEL
In order to determine if late gene expression contributes to the
decrease of BimEL expression, Mutu-I and Akata cells were
pretreated for 1 h with 100 μM PAA prior to stimulation respectively
with TGF-β1 or anti-Ig for various periods of time. BimEL, phospho-
ERK 1/2, ERK 1/2, ZEBRA and VCA were assayed by western-blot at
different times after induction. As shown in Figs. 2 and 3, two levels
of downregulation of BimEL occur after EBV reactivation in Mutu-I or
Akata cells. The ﬁrst step was observed at 4 or 8 h after treatmentFig. 1. Levels of ZEBRA, Bcl-2, Bcl-xL, Bid, Bim (EL, L and S), Bax and Puma expression in
Mutu-I and Akata cells upon EBV reactivation. Cells were incubated in the absence or
presence of TGF-β1 (2 ng/ml) or anti-Ig (7.5 μg/ml). The expression of the immediate
early EBV protein ZEBRA was analyzed by western blotting 17 h later, using the speciﬁc
monoclonal antibody Z125. The membrane was then reprobed separately with a panel
of speciﬁc antibodies directed against Bcl-2, Bcl-xL, Bid, Bim, Bax, Puma and tubulin
(loading control).
quantiﬁed with the ImageJ software. The medium and the standard deviation, calculated
from two independent experiments, are represented.with TGF-β1 or anti-Ig, (during EBV-early-lytic cycle); this ﬁrst drop
in the BimEL level was similar whether or not the Mutu-I or Akata
cells were pretreated with PAA. Thus, this decrease did not depend
on the EBV late-lytic cycle. However, in Mutu-I and Akata cells
induced respectively by TGF-β1 or anti-Ig, a dramatic second drop of
the BimEL level was observed at 16 or 48 h post-treatment. It
occurred late in the EBV cycle, when VCA were detected. PAA
treatment (which is non-toxic to B cells (not shown)) led to
inhibition of the second drop in BimEL expression. Thus, the second
decrease in BimEL expression is PAA sensitive, showing that late
product(s) of the EBV cycle contributed directly or indirectly to
downregulation of BimEL expression.
EBV-negative BL cells BJAB or DG75 treated with anti-Ig (Fig. 4)
or TGF-β1 respectively (Fig. 5) exhibited only one drop of
downregulation of BimEL expression whether or not PAA was
used. This result suggest that the ﬁrst decrease of BimEL expression
might be EBV independent while the second one is indeed EBV
late lytic cycle dependent. We observed that neither TGF-β1 nor
anti-Ig treatment affected the viability of the cells used in this
study (Fig. 6).
Twenty nine percent of Mutu-I or 32% of Akata cells, treated
respectively with TGF-β1 or anti-Ig, express VCA proteins (Table 1).
The cells labelled with VCA antibodies were negative for Bim
expression and we never observed VCA staining in Bim positive cells
(data not shown).
Fig. 4. BimEL degradation in BJAB cells upon treatment with anti-Ig. (A) BJAB cells were
pretreated or not for 1 h with PAA and then stimulated with anti-Ig for 4, 8, 16, or 48 h.
At the indicated time, cells were harvested, washed, lysed; extracts were analyzed by
western blotting against BimEL, phospho-ERK 1/2, ERK 1/2, and tubulin (loading
control) antibody binding was detected by enhanced-chemiluminescence. Images were
captured using a DDC camera (LAS-1000; Fuji system). (B) The signal was quantiﬁed
with the ImageJ software. The medium and the standard deviation, calculated from two
independent experiments, are represented.
Fig. 5. BimEL degradation in DG75 cells upon treatment with TGF-β1. (A) DG75 cells
were pretreated or not for 1 h with PAA and then stimulated with TGF-β1 for 4, 8, 16, or
48 h. At the indicated time, cells were harvested, washed, lysed and extracts were
analyzed by western blotting against BimEL, phospho-ERK 1/2, ERK 1/2, and tubulin
(loading control). Antibody binding was detected by enhanced-chemiluminescence.
Images were captured using a DDC camera (LAS-1000; Fuji system). (B) The signal was
quantiﬁed with the ImageJ software. The medium and the standard deviation,
calculated from two independent experiments, are represented.
Fig. 3. EBV-late-gene expression contributes to BimEL degradation during virus
reactivation. (A) Akata cells were pretreated or not for 1 h with PAA and then stimulated
with anti-Ig for 4, 8, 16, or 48 h. At the indicated time, cells were harvested, washed, lysed;
extracts were analyzed by western blotting against BimEL, phospho-ERK 1/2, ERK 1/2,
ZEBRA, VCA and tubulin (loading control). Antibody binding was detected by enhanced-
chemiluminescence. Images were captured using a DDC camera (LAS-1000; Fuji system).
(B) The signal was quantiﬁed with the ImageJ software. The medium and the standard
deviation, calculated from two independent experiments, are represented.
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BimEL expression
It was reported that BimEL degradation depends on its phosphor-
ylation by ERK 1/2 MAPKinase in different types of cells including BL
cells (Ley et al., 2003; Luciano et al., 2003). We checked whether this
pathway could be involved in regulation of BimEL level in Mutu-I, and
Akata cells upon TGF-β1, or anti-Ig treatments. We induced EBV
reactivation in these cell lines using the indicated EBV inducer agents
either with or without pretreatment by ERK 1/2 MAPKinase inhibitor
U0126 (50 μM) and BimEL protein expression was investigated by
western blot. As shown in Fig. 7, inhibition of the ERK 1/2 MAPKinase
pathway by U0126 led to a restoration of the initial level of BimEL in
Mutu-I and Akata cells. Thus, the activated ERK 1/2 MAPKinase
pathway plays a crucial role in regulating BimEL expression. However,
as ERK 1/2 is required for ZEBRA expression, and consequently for late-
gene expression, treatment with U0126 will lead to inhibition of all the
events subsequent to ZEBRA expression, including the second drop in
BimEL level, explaining why the use of U0126 restored the initial level
of BimEL. Phosphorylation of ERK 1/2 was not affected by PAA (Figs. 2
and 3), suggesting that the second drop in the BimEL protein did not
require an increase in the phosphorylation level of ERK 1/2 proteins.
Phosphorylation of Ser69 of the BimEL protein does not modulate the
drop of BimEL level induced by EBV-late-gene expression
It was shown that BimEL, when phosphorylated on Ser69 by ERK
1/2, is rapidly degraded via the proteasome pathway (Luciano et
Fig. 6. Effects of TGF-β1 or anti-Ig treatment on cell viability. Viability of Mutu-I, Akata, DG75, and BJAB cells following stimulation for 4, 8, 16, or 48 h with TGF-β1 or anti-Ig was
assayed using a LIVE/DEAD reduced biohazard viability/cytotoxicity kit (Invitrogen). Staining and analysis were performed as recommended by the manufacturer. Ability of this kit
to detect cell death was controlled using a treatment of the cells with 0.4 mM of MnCl2.
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western-blot using speciﬁc antibodies in Mutu-I and Akata cells
pretreated or not with MG262 a speciﬁc proteasome inhibitor, and
then treated or not with TGF-β1 or anti-Ig respectively. The EBV-
negative cells DG75 and BJAB cells were also treated with MG262
prior to incubation with TGF-β1 or anti-Ig. The results presented in
Fig. 8, showed that Bim phosphorylation resulted from TGF-β1 as
well as anti-Ig treatments in EBV-positive as well as in EBV-
negative cells. EBV-late-gene expression did not change the level of
Bim phosphorylated at residue Ser69. Moreover, when Mutu-I or
Akata cells were pretreated with both PAA and MG262, and then
induced respectively by TGF-β1 or anti-Ig, the level for phospho-
BimEL Ser69 remained unchanged (Fig. 9). These results suggested
that the mechanism(s) involved for the second drop of BimEL
expression did not depend on phosphorylation of BimEL on Ser69
by ERK 1/2.
Effect of the proteasome inhibitor on BimEL expression
We investigated the possible mechanism underlying the effect
of EBV reactivation on the expression of BimEL. As cited above,
ERK 1/2-mediated phosphorylated BimEL has been shown to be
degraded by the proteasome pathway (Luciano et al., 2003;
Clybouw et al., 2005). The effect of MG262 on BimEL level was
examined upon stimulation by TGF-β1 or anti-Ig. Mutu-I, andTable 1
Percentage of VCA-expressing cells upon TGF-β1 or anti-Ig treatment of Mutu-I or Akata
cells respectively, determined by immunoﬂuorescence
Cell line No treatment TGF-β1 or anti-lg
treated cells
Mutu-l 2.2% 29.4%
Akata 3.7% 32.6%Akata cells were incubated (or not) with MG262 (250 nM) for 1 h
prior to stimulation with the indicated EBV-inducer agent. This
treatment did not affect cell viability (Fig. 10). BimEL expression was
then examined, in cell extracts at 48 h post-treatment. Whereas,
MG262 alone had no effect, simultaneous treatment of Mutu-I or
Akata cells with both TGF-β1 or anti-Ig respectively, and MG262
led to a restoration of BimEL levels to that seen in the absence of
TGF-β1 or anti-Ig (Fig. 7). This result suggests that the two drops in
the level of BimEL expression depended on its degradation by the
proteasome.
The decrease of the BimEL level is due to a post-transcriptional mechanism
Semi-quantitative reverse transcription-PCR (RT-PCR) analysis
was performed to determine if this observed downregulation of
BimEL expression resulted from a modulation of the transcript level.
While the signal obtained when the cDNA encoding the ZEBRA
protein showed a marked ampliﬁcation after EBV reactivation,
the ampliﬁcation products corresponding to BimEL were similar in
both uninduced and induced EBV-positive BL cells (Fig. 11)
suggesting that the lower levels of BimEL protein observed upon
EBV reactivation were not due to a decrease of the steady state of
RNA level.
Discussion
EBV contributes to the development of B-cell malignancies.
Several factors encoded and/or regulated by the virus contribute to
transformation. Downregulation of the proapoptotic Bim protein is
a critical regulator of B cell survival and reduced expression is a
major determinant of lymphoproliferation. Clybouw et al. (2005,
2008) showed that latent EBV-infection of BL cells led to down-
regulation of BimEL expression through proteasomal degradation.
This event was dependent of activation of the ERK 1/2 MAPK
pathway.
Fig. 7. Regulation of BimEL expression upon EBV reactivation requires activated ERK 1/2 and proteasome pathways. Mutu-I (A) or Akata (B) cells were incubated 48 h respectively
with TGF-β1 (2 ng/ml) or anti-Ig (7.5 μg/ml) either with or without a pretreatment byMG262 (250 nM) or U0126 (50 μM) as indicated. Equal amounts of cell extracts were analyzed
by western blotting with antibodies to Bim, phospho-ERK 1/2, ERK 1/2, ZEBRA, and to tubulin (loading control). Antibody binding was detected by enhanced-chemiluminescence.
Imageswere captured using a DDC camera (LAS-1000; Fuji system). (C and D) The signal was quantiﬁedwith the ImageJ software. Themedium and the standard deviation, calculated
from two independent experiments, are represented.
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BimEL protein not only occur through in vitro EBV infection of BL cells
but also during viral reactivation induced in BL cell lines derived
from in vivo EBV-infected tumours. Our data show that EBV
reactivation was associated with dramatic decrease of BimEL in
Mutu-I, and Akata cells, whereas, the amounts of Bcl-2, Bcl-xL, Bid,
Puma, Bax, Bim L and S remained constant within a given cell line. As
schematized in Fig. 12, we demonstrated that a two steps down-
regulation of expression of the proapoptotic protein BimEL occurred
during EBV reactivation in BL cell lines, through the proteasome
pathway. The ﬁrst drop, taking place during the early gene
expression, was dependent on ERK 1/2 phosphorylation, and might
be EBV-independent because (i) virus reactivation can be dissociated
from this ﬁrst reduction of BimEL level, since treatment with MG262
proteasome inhibitor did not reduce ZEBRA-induced expression
(Fig. 7) and (ii) a single step of decrease in BimEL level was observed
in EBV-negative BL treated with TGF-β1 or anti-Ig (Figs. 4 and 5). We
showed for the ﬁrst time that, a second dramatic drop of the BimEL
level, took place during the late phase of the EBV lytic cycle. This
decrease was dependent of EBV replication/EBV-late gene expres-
sion. Mechanisms involved in this step were different from the ones
involved in those already described because this decrease was ERK 1/
2 independent since a long term ERK 1/2 phosphorylation did not
produce another step in the decrease of BimEL level in EBV-negative
cell lines (Figs. 4 and 5). Moreover, our ﬁndings demonstrated for the
ﬁrst time, that the lytic cycle contributes directly or indirectly to
downregulation of BimEL. Furthermore our results suggest that
although the EBV-late gene-dependent drop in BimEL was protea-some dependent, phosphorylation of Ser69 residue was not crucial
for this event.
Several EBV genes, LMP1, BHRF1, BALF1, inhibit apoptosis. It was
shown that late EBV lytic cycle was also able to suppress (or at least
delay signiﬁcantly) this process (Inman et al., 2001). However the
cellularmoleculesmodulating this effect were not identiﬁed. As Bim is
a critical regulator of B cell survival, this event might participate in
resistance to death. It was shown that during the lytic cycle EBV may
actively block the cell death program and our work provide a
mechanism by which EBV lytic gene expression is protective against
apoptosis. We propose that downregulation of BimEL, caused directly
or indirectly by EBV-late-gene expression, could contribute to
induction of BimEL degradation and then to evasion from apoptosis,
preventing premature cell death of the host cell during virus particle
production.
Materials and methods
Cell culture and reagents
Mutu-I (Gregory et al., 1990), Akata (Takada et al., 1991) are EBV-
positive BL cell lines, BJAB (Klein et al., 1974) and DG75 (Ben-Bassat et
al., 1977) are EBV-negative BL cell lines. Cells were grown in RPMI
1640 supplemented with 2 mM glutamine (GIBCO BRL Life Technol-
ogies, Grand Island, N.Y.), 100 μg/ml primocin (CAYLA, Toulouse,
France), and 10% heat-inactivated fetal calf serum (FCS) (GIBCO BRL
Life Technologies, Grand Island, N.Y.). For induction of the EBV lytic
cycle,Mutu-I, andAkata cellswere stimulated respectivelywith 2 ng/ml
Fig. 8. Phosphorylation of Bim in EBV-positive and negative cells upon stimulation with TGF-β1 or anti-Ig. Mutu-I, Akata, DG75 and BJAB cells were pretreated or not with MG262,
and then stimulated with TGF-β1 or anti-Ig for 4, 8, 16 or 48 h. At the indicated time point, cells were harvested, washed, lysed; extracts were then analyzed by western blotting
against BimEL, phospho-Bim, phospho-ERK 1/2, ERK 1/2, ZEBRA (for Mutu-I and Akata) and tubulin (loading control).
Fig. 9. EBV-late-gene expression does not affect phosphorylation of Bim on Ser69 in
reactivated cells. Mutu-I and Akata, cells were pretreated separately or simultaneously
with MG262, and PAA, prior to stimulation with TGF-β1 or anti-Ig for 48 h. Cells were
harvested, washed, lysed; extracts were then analyzed by western blotting against
BimEL, phospho-Bim, and tubulin (loading control).
46 L. Oussaief et al. / Virology 387 (2009) 41–49of TGF-β1 (R&D SystemsMinneapolis, MN, USA) or 7.5 μg/ml of human
anti-Ig (Dako, Denmark) in a reduced fetal calf serum medium
concentration (0.5%). U0126, MG262 was obtained from Calbiochem
(VWR international, France), and PAA was purchased from Sigma
(St. Louis, MO, USA). All experiments were repeated at least twice
at different times.
Antibodies
The anti-ZEBRA monoclonal antibody Z125 was a generous gift
from E. Drouet (Faculté de Pharmacie, Grenoble, France). The
antibodies against Bim, Bax, Bcl-2 and Bcl-xL were purchased from
Santa-Cruz Biotechnology (Santa-Cruz, CA). The antibodies against
Puma, Bid, phospho-Bim (Ser69), ERK 1/2, phospho-ERK 1/2 and
tubulin were purchased from Cell Signalling Technology (Beverly,
MA, USA). The human anti-VCA antibody was obtained from Ortho
Diagnostic System, Inc. (Raritan, New Jersey). The rabbit peroxidase-
conjugated IgG, the human peroxidase-conjugated IgG, and the
mouse peroxidase-conjugated IgG from Sigma (St. Louis, MO, USA)
were used as secondary antibodies. The rabbit monoclonal to Bim
(Abcam, Cambridge, UK), the antibodies against VCA (Biotech
Laboratories), the donkey anti-rabbit Alexa 488 antibodies (Inter-
chim, Montlucon, France), and the goat anti-mouse Alexa 594
antibodies (Invitrogen, Cergy pontoise, France) were used for
ﬂuorescence microscopy analysis.
Immunoblot analysis
Cells were harvested, washed brieﬂy with phosphate-buffered
saline, resuspended in a buffer composed of 100 mM Tris–Cl (pH 7.6),
50 mM NaCl, 2 mM EDTA, 0.5% NP-40, phenylmethylsulfonyl ﬂuoride
Fig.10. Effects of MG262 and U0126 on cell viability. Viability of Mutu-I and Akata cells following 48 h of the indicated treatments, was assayed using a LIVE/DEAD reduced biohazard
viability/cytotoxicity kit (Invitrogen). Staining and analysis were performed as recommended by the manufacturer. Ability of this kit to detect cell death was controlled using a
treatment with 0.4 mM of MnCl2.
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ml, and sonicated. Protein concentration was determined using Micro
BCA™ Protein Assay Kit from Pierce Biotechnology. An equal amount
of protein in loading buffer, heated for 5 min at 100 °C and separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) on 10–12% gels were transferred by electroblotting to a
nitrocellulose membrane (Schleicher & Schuell, Ecquevilly, France).
Membranes were reacted with the indicated primary antibodies using
the appropriate dilution as indicated by themanufacturer, followed by
treatment with a horseradish peroxidase-conjugated IgG (anti-rabbit,
anti-mouse, or anti-human IgG Ab (1:2000–1:4000)) from Sigma (St.
Louis, MO, USA). Membranes were visualized with enhanced-
chemiluminescence (West-pico or femto; Pierce Biotechnology).
Images were captured using a DDC camera (LAS-1000; Fuji system).
Immunoﬂuorescence microscopy
Mutu-I and Akata cells were incubated or not with TGF-β1 (2 ng/
ml) or anti-Ig (7.5 μg/ml) respectively for 12 h at 37 °C, washed in
PBS, plated on glass slides, air dried and ﬁxed in ice-cold acetone for
10 min. Fixed cells were incubated with anti-VCA murine mono-
clonal antibodies (1/100) or with rabbit anti-Bim monoclonal
antibodies (1/100), for 1 h at 37 °C. After three 5 min washes in
PBS, the cells were incubated with goat anti-mouse immunoglobulinFig. 11. Downregulation of BimEL expression upon EBV reactivation results from a post-tra
micrograms of total RNA from cells uninduced and after 17 h of induction, were reverse transc
various ampliﬁcation cycle numbers; cDNA of HPRT was used as internal control.(1/20) or with anti-rabbit IgG (1/500) for 1 h at 37 °C. Cells were
stained with 4,6-diamidino-2-phenylindole (DAPI) (Sigma, St. Louis,
MO, USA). Finally, images were obtained with a Leica LEI-750 system
using the Leica LIDA 1.55 software (Acusoft coorporation).
RT-PCR
Total RNA from each uninduced and induced EBV-positive cells
lines was isolated using TRIzol reagent and Rnase inhibitors (Invitro-
gen, Carlsbad, CA) according to the manufacturer's protocol. RNA
concentration was determined spectrophotometrically. The template
cDNAwas synthesized by reverse transcription of the total RNA (3 μg)
with Moloney murine leukemia virus reverse transcriptase (Promega,
Madison, WI) using an oligo (dT)15 primer (Promega). The primers
used for PCR ampliﬁcations included: 5′-TGATGTAAGTTCTGAGTGTG-
3′, 5′-ACGTAAGAGTCGTAAGATAA-3′ for BimEL (Clybouw et al., 2005),
and 5′-TTACACCTGACCCATACCAG-3′, 5′-ACATCTGCTTCAACAGGAGG
for ZEBRA (Arbach et al., 2006). cDNA of HPRT was used as internal
control as previously performed (Touitou et al., 2003).
Determination of cell viability
Cells viability was assessed using LIVE/DEAD reduced biohazard
viability/cytotoxicity test, Molecular Probes, Invitrogen (Cergynscriptional event. Semi-quantitative RT-PCR assay of ZEBRA and BimEL cDNA: Three
ribed. cDNA of ZEBRA and BimEL were then analyzed by semi quantitative RT-PCR using
Fig. 12. Activation of the EBV lytic program leads to a two steps downregulation of expression of the proapoptotic protein BimEL. Anti-Ig or TGF-β1 treatment provokes ERK 1/2
phosphorylation (inhibited by U0126), leading to a ﬁrst drop of BimEL level. ERK 1/2 activation is required for switching to the EBV lytic cycle, with the expression of immediate early,
early and late genes (the last inhibited by PAA). Late product(s), directly or indirectly provoke(s) a second decrease in BimEL. Both decreases depend on the proteasome pathway
(inhibited by MG262).
48 L. Oussaief et al. / Virology 387 (2009) 41–49Pontoise, France). Staining and analysis were performed as
recommended by the manufacturer. Ability of this kit to detect
cell death was controlled using a treatment with 0.4 mM of MnCl2
(El Mchichi et al., 2007). Cell numbers were determined with a
Neubauer-counting chamber.
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